Technical Analysis for AZN - Astrazeneca Plc

Grade Last Price % Change Price Change
grade F 6794.0 -4.87% -348.00
AZN closed down 4.87 percent on Friday, February 28, 2020, on 2.55 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Extremely Strong Down Down Down
Historical AZN trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -4.87%
Slingshot Bearish Bearish Swing Setup -4.87%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Articles Natural Sciences Pharmaceutical Industry Biopharmaceutical Life Sciences Pharmacy Infection Neuroscience Chronic Kidney Disease Heart Failure Astrazeneca

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 72750.0
52 Week Low 109.5114
Average Volume 2,067,788
200-Day Moving Average 7082.98
50-Day Moving Average 7601.58
20-Day Moving Average 7494.35
10-Day Moving Average 7386.80
Average True Range 654.59
ADX 83.13
+DI 71.02
-DI 13.01
Chandelier Exit (Long, 3 ATRs ) 5856.24
Chandelier Exit (Short, 3 ATRs ) 8652.76
Upper Bollinger Band 7945.64
Lower Bollinger Band 7043.06
Percent B (%b) -0.28
BandWidth 12.04
MACD Line -119.30
MACD Signal Line -52.36
MACD Histogram -66.9333
Fundamentals Value
Market Cap 85.87 Billion
Num Shares 12.6 Million
EPS 134.00
Price-to-Earnings (P/E) Ratio 50.70
Price-to-Sales 225.35
Price-to-Book 319.20
PEG Ratio 41.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7473.50
Resistance 3 (R3) 7514.00 7328.00 7360.25
Resistance 2 (R2) 7328.00 7154.95 7307.75 7322.47
Resistance 1 (R1) 7061.00 7048.05 6968.00 7020.50 7284.73
Pivot Point 6875.00 6875.00 6828.50 6854.75 6875.00
Support 1 (S1) 6608.00 6701.95 6515.00 6567.50 6303.27
Support 2 (S2) 6422.00 6595.05 6401.75 6265.53
Support 3 (S3) 6155.00 6422.00 6227.75
Support 4 (S4) 6114.50